GSK3B and acute myeloid leukemia: The presence of non-GSK3β-bound β-catenin predominantly in the nucleus is recognised as being important in the pathogenesis of AML and patient prognosis, highlighting the clinical potential of targeting the Wnt pathway [15, 24–28].